Caris Life Sciences, Inc.
CAIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. Valued at $7.09B, CAI is a mid-cap name in its sector. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Market Cap
$7.09B
Beta
—
P/E (TTM)
2.64
P/E (Fwd)
66.35
EPS (TTM)
$9.50
EPS (Fwd)
$0.38
ROE
20.1%
ROA
8.8%
Cash
$793.1M
Total Debt
$452.4M
Free CF
$63.3M
52W Change
-27.3%
Annual Financials
Cash vs Debt
Where CAI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CAI finished 30.18% above its 150-day moving average ($19.05) and 18.49% above its 200-day moving average ($20.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CAI overbought or oversold?
At the September 3, 2026 close, CAI's RSI(14) was 61.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $793.1M in cash and $452.4M in debt, CAI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $63.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 20.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $258.5M (2022) to $812.0M (2025), reflecting a 214% increase over the period.
Investors considering Caris Life Sciences, Inc. should weigh the typical risks associated with CAI's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing CAI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.